We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Selcia Awarded GMP Certificate for Preparation and Carbon-14 Labelling of APIs for Clinical Trials
News

Selcia Awarded GMP Certificate for Preparation and Carbon-14 Labelling of APIs for Clinical Trials

Selcia Awarded GMP Certificate for Preparation and Carbon-14 Labelling of APIs for Clinical Trials
News

Selcia Awarded GMP Certificate for Preparation and Carbon-14 Labelling of APIs for Clinical Trials

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Selcia Awarded GMP Certificate for Preparation and Carbon-14 Labelling of APIs for Clinical Trials"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Selcia Limited, an independent provider of Carbon-14 (C-14) radiolabelling services, announces that its radiochemistry facility has been granted a Good Manufacturing Practice (GMP) certificate for the preparation and C-14 labelling of Active Pharmaceutical Ingredients (APIs) for clinical trials following a successful inspection by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

Commenting on the award, Selcia’s Managing Director, Dr Hans Fliri said: “With market demand increasing for GMP radiolabelling, we are pleased that we can now offer pharmaceutical and biotech companies cost effective radiolabelling services to support both the pre-clinical and clinical development of their new medicines. Selcia’s extended capability of now being able to produce GMP radiolabelled API material will shorten the timeframe for our clients to commence key Phase 1 clinical trials”.

Director of Radiochemistry Dr Gill Little said: “Our radiochemistry team continues to focus on delivering the best possible tailored service. Together with our GLP analytical laboratory we can supply the high quality products that our customers expect”.
Advertisement